Hexocyclium Methylsulfate
A methylsulfate salt form of hexocyclium, an anticholinergic antispasmodic used to reduce gastric acid secretion and bowel spasms in the management of peptic ulcer disease and gastrointestinal disorders. The methylsulfate form improves the drug's stability and pharmaceutical properties. As with other anticholinergics, side effects include dry mouth, blurred vision, and urinary retention.
Молекулярная масса
428,6000 g/mol
TPSA
98,30 Ų
Механизм действия
Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.
2D Структура
Cite this structure
Embed this structure
SMILES
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1
InChI
InChI=1S/C20H33N2O.CH4O4S/c1-22(2)15-13-21(14-16-22)17-20(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19;1-5-6(2,3)4/h3,5-6,9-10,19,23H,4,7-8,11-17H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
Molecular Formula
C21H36N2O5S
HBD / HBA
1 / 6
Вращаемые Связи
4
Тяжёлые Атомы
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Часто задаваемые вопросы
A methylsulfate salt form of hexocyclium, an anticholinergic antispasmodic used to reduce gastric acid secretion and bowel spasms in the management of peptic ulcer disease and gastrointestinal disorders. The methylsulfate form improves the drug's stability and pharmaceutical properties. As with other anticholinergics, side effects include dry mouth, blurred vision, and urinary retention.
Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.
Yes, Hexocyclium Methylsulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1626570. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 101587. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hexocyclium-methylsulfate"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hexocyclium-methylsulfate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hexocyclium-methylsulfate/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hexocyclium-methylsulfate/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hexocyclium-methylsulfate"></drugfyi-drug>